Merck Past Earnings Performance

Past criteria checks 4/6

Merck's earnings have been declining at an average annual rate of -0.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 9.1% per year. Merck's return on equity is 34%, and it has net margins of 22%.

Key information

-0.5%

Earnings growth rate

-0.2%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	9.1%
Return on equity	34.0%
Net Margin	22.0%
Next Earnings Update	31 Oct 2024

Recent past performance updates

Recent updates

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Jul 31

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

May 22

Revenue & Expenses Breakdown

How Merck makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:MRK Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	62,480	13,736	9,887	8,235
31 Mar 24	61,403	2,306	9,839	18,592
31 Dec 23	60,115	365	9,884	18,342
30 Sep 23	59,315	4,608	10,226	12,481
30 Jun 23	58,311	3,111	9,934	12,685
31 Mar 23	57,869	13,030	9,851	12,433
31 Dec 22	59,283	14,519	9,669	11,918
30 Sep 22	58,974	15,322	10,119	11,923
30 Jun 22	57,169	16,641	9,776	10,940
31 Mar 22	53,978	13,910	9,489	10,515
31 Dec 21	48,704	12,345	9,403	11,942
30 Sep 21	46,131	5,908	9,260	10,725
30 Jun 21	43,906	3,665	8,845	10,678
31 Mar 21	41,857	4,793	8,669	10,339
31 Dec 20	41,518	4,519	8,569	10,564
30 Sep 20	42,438	9,492	8,812	9,079
30 Jun 20	43,906	9,070	9,200	8,818
31 Mar 20	46,312	9,399	9,700	8,990
31 Dec 19	39,121	5,690	8,829	8,594
30 Sep 19	45,970	9,314	9,604	8,489
30 Jun 19	44,367	9,362	9,586	7,997
31 Mar 19	43,073	8,399	9,467	8,084
31 Dec 18	42,294	6,220	9,587	9,254
30 Sep 18	41,729	3,347	9,541	9,251
30 Jun 18	41,259	1,341	9,554	11,680
31 Mar 18	40,725	1,579	9,449	11,182
31 Dec 17	40,122	2,394	9,560	9,845
30 Sep 17	39,804	2,845	9,615	9,427
30 Jun 17	40,016	5,086	9,612	6,916
31 Mar 17	39,929	4,346	9,713	7,035
31 Dec 16	39,807	3,920	9,313	6,921
30 Sep 16	39,907	5,492	9,193	6,849
30 Jun 16	39,444	5,133	9,312	6,828
31 Mar 16	39,385	4,614	9,776	6,518
31 Dec 15	39,498	4,442	9,799	6,613
30 Sep 15	39,765	10,781	10,262	6,727
30 Jun 15	40,249	9,850	10,756	6,644
31 Mar 15	41,398	11,168	10,818	6,685
31 Dec 14	42,237	11,920	11,172	6,532
30 Sep 14	43,075	5,385	11,501	6,435
30 Jun 14	43,550	5,614	11,304	6,544
31 Mar 14	43,626	4,516	11,511	6,774
31 Dec 13	44,033	4,404	11,672	7,123
30 Sep 13	44,450	4,531	12,084	7,563

Quality Earnings: MRK has a large one-off loss of $13.6B impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: MRK's current net profit margins (22%) are higher than last year (5.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MRK's earnings have declined by 0.5% per year over the past 5 years.

Accelerating Growth: MRK's earnings growth over the past year (341.5%) exceeds its 5-year average (-0.5% per year).

Earnings vs Industry: MRK earnings growth over the past year (341.5%) exceeded the Pharmaceuticals industry 32.4%.

Merck Past Earnings Performance

Past criteria checks 4/6

Key information

Recent past performance updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

First quarter dividend of US$0.77 announced

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck: Positive Developments, But Watch The Q2 Earnings

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck: Among The Best Health Care GARP Plays Today

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension (PAH)

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma

Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

First quarter dividend of US$0.77 announced

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Eyebiotech Limited for $3 billion.

Merck Declares Dividend for the Third Quarter of 2024, Payable on July 8, 2024

Merck Stock: Still Discounted To Graham P/E

Merck Announces Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies